Eligibility criteria and selection of studies
The SR included RCTs comparing dupilumab versus placebo added to usual care/standard of care in patient with moderate-to-severe AD, and reporting one of the outcomes of interest as formulated by the GDG (figure 1 A and B). The SR excluded studies with dose or route not approved by the EMA or FDA, papers published as abstract or conference communications or not published in English. After initial calibration two reviewers independently screened the search results based on the title and abstract followed by independent assessment of the eligibility based on the full text. In case of disagreement a third reviewer was consulted. References were managed with Endnote version X9 software (Thomson Reuters, New York, USA).